Publications by authors named "B Zaric"

Lung cancer is among the lethal and most prevalent oncological diseases globally. It is known that two types of mutations, namely anaplastic lymphoma kinase (ALK) gene rearrangement and epidermal growth factor receptor (EGFR) gene mutation, are responsible for the development of lung adenocarcinoma. The present study aimed to investigate the differences in the frequency of clinical, cytomorphological and histomorphological features of ALK and EGFR-positive lung adenocarcinomas.

View Article and Find Full Text PDF

Unlabelled: Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia.

View Article and Find Full Text PDF

: Death is an unavoidable experience in any person's life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings.

View Article and Find Full Text PDF

After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen.

View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib, a third-generation EGFR tyrosine kinase inhibitor, was tested in a global phase III study (LASER301) against gefitinib for treating patients with advanced non-small-cell lung cancer (NSCLC) who had specific EGFR mutations.
  • The study included 393 treatment-naïve patients and found that those taking lazertinib had a significantly longer median progression-free survival (20.6 months) compared to gefitinib (9.7 months), with similar overall response rates for both treatments.
  • Ultimately, lazertinib showed improved efficacy over gefitinib in managing advanced NSCLC, while maintaining a safety profile consistent with previous findings.
View Article and Find Full Text PDF